risdiplam

Ukraine

Drugs containing this active substance

EVRISDI

The drug is indicated for the treatment of 5q-associated spinal muscular atrophy (SMA) in pediatric and adult patients.

Form: powder for oral solution

Active substance	Dosage
risdiplam	0.75 mg/ml

Manufacturer: F. Hoffmann-La Roche Ltd (manufacturing of unpackaged product, primary packaging (bottling stage), quality control testing, secondary packaging, batch release; manufacturing of unpackaged product, primary packaging (bottling stage), quality control testing (microbiological purity testing))